Research Article
Combination Intensity-Modulated Radiotherapy and Sorafenib Improves Outcomes in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
| | Adverse event | IMRT + sorafenib (n = 36) | IMRT (n = 46) | value | | Grade 1 (%) | Grade 2 (%) | Grade 3 (%) | Grade 1 (%) | Grade 2 (%) | Grade 3 (%) | Any grade |
| | Nausea | 11 (30.6) | 4 (11.1) | 0 (0.0) | 12 (26.1) | 1 (2.2) | 0 (0.0) | 0.146 | | Vomiting | 6 (6.7) | 2 (5.6) | 0 (0.0) | 8 (17.4) | 0 (0.0) | 0 (0.0) | 0.515 | | Anorexia | 19 (52.8) | 3 (8.3) | 0 (0.0) | 22 (47.8) | 1 (2.2) | 0 (0.0) | 0.223 | | Abdominal pain | 18 (50.0) | 2 (5.6) | 0 (0.0) | 16 (34.8) | 1 (2.2) | 0 (0.0) | 0.085 | | Fatigue | 24 (66.7) | 3 (8.3) | 0 (0.0) | 22 (47.8) | 2 (4.3) | 0 (0.0) | 0.035 | | Skin reactions | 18 (50.0) | 2 (5.6) | 0 (0.0) | 16 (34.8) | 0 (0.0) | 0 (0.0) | 0.043 | | Leukopenia | 12 (33.3) | 12 (33.3) | 3 (8.3) | 23 (50.0) | 7 (15.2) | 1 (2.2) | 0.056 | | Thrombocytopenia | 12 (33.3) | 11 (30.6) | 5 (13.9) | 11 (23.9) | 13 (28.3) | 6 (13.0) | 0.452 | | Anemia | 4 (11.1) | 5 (13.9) | 1 (2.8) | 10 (21.7) | 3 (6.5) | 0 (0.0) | 0.799 | | Increased ALT level | 12 (33.3) | 3 (8.3) | 0 (0.0) | 12 (26.1) | 1 (2.2) | 0 (0.0) | 0.166 | | Increased AST level | 19 (52.8) | 1 (2.8) | 0 (0.0) | 18 (39.1) | 1 (2.2) | 0 (0.0) | 0.209 | | Increased GGT level | 18 (50.0) | 7 (19.4) | 2 (5.6) | 17 (37.0) | 7 (15.2) | 3 (6.5) | 0.239 |
|
|
